Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 62Breast Neoplasms 44Prostatic Neoplasms 35Lung Neoplasms 29Multiple Myeloma 24Neoplasms 22Colorectal Neoplasms 19Parkinson Disease 4, Autosomal Dominant Lewy Body 18Ovarian Neoplasms 17Neoplasm Metastasis 17Leukemia, Lymphocytic, Chronic, B-Cell 17Carcinoma, Renal Cell 15Pancreatic Neoplasms 13Small Cell Lung Carcinoma 12Endometrial Neoplasms 12Urinary Bladder Neoplasms 10Stomach Neoplasms 10Squamous Cell Carcinoma of Head and Neck 10Leukemia, Myeloid, Acute 10Myasthenia Gravis 9Lymphoma, Follicular 9Fallopian Tube Neoplasms 9Non-Muscle Invasive Bladder Neoplasms 8Colonic Neoplasms 8Recurrence 7Burkitt Lymphoma 7Lymphoma, Mantle-Cell 6Esophageal Neoplasms 6Carcinoma 6Biliary Tract Neoplasms 6

Interventions

zanidatamab 1tislelizumab 1sitravatinib 1pamiparib 1lenvatinib 1Temozolomide 1HMPL-013 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Advanced Malignancies × 30 days × Clear all
NCT04164199 2026-06-03

Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies

BeOne Medicines

Phase 3 Completed
404 enrolled

Advanced Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡